" class="no-js "lang="en-US"> James M. Mackay - Medtech Alert
Saturday, April 04, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
James Mackay

James M. Mackay

About James M. Mackay

Distinguished scientist and global life sciences business leader with strong record of bringing multiple drugs to market and patients

|| Strategic thinker with ability to define and implement strategic vision through clear communication and innovative operational delivery

|| Develops strategic and operational partnerships, and builds inspiring cultures via authenticity, development of mutual trust, empowerment and mentoring

|| Creates transparent and open environments allowing staff to raise concerns, cultivating deep thinking, and achieving breakthrough results

|| Experience running large pharmaceutical and small biotechnology businesses with ability to work across international boundaries and cultures, enhancing delivery through diversity

|| Value-driven decision making, the courage to make tough decisions to achieve value-added delivery to the business, and a purposefulness and drive to deliver an outcome that creates positive and lasting change

CAREER HIGHLIGHTS

• Led successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca

• Achieved FDA and EMA approval of Zurampic, the first novel MOA for the treatment of gout
in over 50 years

• Led successful commercial licensing of Zurampic and Duzallo to Ironwood Pharmaceuticals and
Grunenthal

• Transformed the AstraZeneca/BMS Diabetes global development and commercial collaboration, and
established Onglyza, Kombiglyze XR and Komboglyze as key growth drivers in the AZ portfolio

• Designed and implemented multiple innovative delivery and partnership models including an
industry leading approach to delivery of outsourced clinical work through development of strategic
partnerships with CROs

• Designed and implemented multiple strategic re-organizations, led major global change
management, whilst delivering improved efficiencies and productivity